Clinical Trials Logo

Schizophrenia Schizoaffective clinical trials

View clinical trials related to Schizophrenia Schizoaffective.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05660018 Recruiting - Schizophrenia Clinical Trials

TMS Related Biomarker Assessments

Start date: January 7, 2023
Phase: N/A
Study type: Interventional

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active and sham repetitive transcranial magnetic stimulation (rTMS) in separate sessions. SSD-related biomarkers will be assessed before and after the rTMS administration.

NCT ID: NCT05643196 Recruiting - Schizophrenia Clinical Trials

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

Start date: April 6, 2023
Phase: Phase 2
Study type: Interventional

This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia. Twelve individuals with schizophrenia who report continuous hallucinations or delusions of mild or greater severity will receive one session of PLIFUS and one session of sham PLIFUS in random order, one week apart. If no effect of PLIFUS is detected on measures of functional connectivity or psychotic symptoms in the first four completers, the trial will be changed to 3 sessions of PLIFUS or sham administered over 5 days.

NCT ID: NCT05414058 Recruiting - Clinical trials for Schizophrenia Schizoaffective

Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes

Start date: September 9, 2022
Phase: Phase 2
Study type: Interventional

Two of the major features of schizophrenia spectrum illness, negative and cognitive symptoms, have been associated with poor functional outcome and burden of illness. Given the proposed role of dopaminergic hypoactivity, augmentation with psychostimulants has been postulated as one of the potential treatment options for negative and/or cognitive symptoms of schizophrenia. The major drawback for use of these agents is a potential risk of relapse or worsening of psychosis through direct or indirect dopamine agonism activity and a great deal of caution has been called for use of stimulants in individuals with psychosis. However, preliminary results of earlier studies indicated improvement of negative and cognitive symptoms with off-label use of adjunctive psychostimulants. The present study aims to assess off-label use of adjunct psychostimulants in patients with schizophrenia in a tertiary mental health centre, focusing on efficacy and safety.

NCT ID: NCT04033679 Recruiting - Clinical trials for Schizophrenia;Schizoaffective

The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia

Start date: August 15, 2019
Phase: N/A
Study type: Interventional

This study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia (SCZ). The investigators hypothesize that 20 sessions of tDCS will improve medication nonadherence in patients with SCZ.